tiprankstipranks
Jaguar Animal Health (JAGX)
NASDAQ:JAGX

Jaguar Animal Health (JAGX) Stock Price & Analysis

2,236 Followers

JAGX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.05 - $0.75
Previous Close$0.29
Volume58.06M
Average Volume (3M)71.95M
Market Cap
$82.35M
Enterprise Value$103.95M
Total Cash (Recent Filing)$11.67M
Total Debt (Recent Filing)$33.45M
Price to Earnings (P/E)-0.2
Beta0.68
Aug 14, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding295,474,346
10 Day Avg. Volume50,712,543
30 Day Avg. Volume71,950,095
Standard Deviation0.52
R-Squared0.00864
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)-3.87
Price to Sales (P/S)42.65
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.13
Enterprise Value/Gross Profit10.46
Enterprise Value/Ebitda-4.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

2.98%0.11%0.13%96.78%
0.13% Other Institutional Investors
96.78% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

JAGX FAQ

What was Jaguar Animal Health’s price range in the past 12 months?
Jaguar Animal Health lowest stock price was $0.05 and its highest was $0.75 in the past 12 months.
    What is Jaguar Animal Health’s market cap?
    Currently, no data Available
    When is Jaguar Animal Health’s upcoming earnings report date?
    Jaguar Animal Health’s upcoming earnings report date is Aug 14, 2024 which is in 88 days.
      How were Jaguar Animal Health’s earnings last quarter?
      Currently, no data Available
      Is Jaguar Animal Health overvalued?
      According to Wall Street analysts Jaguar Animal Health’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Jaguar Animal Health pay dividends?
        Jaguar Animal Health does not currently pay dividends.
        What is Jaguar Animal Health’s EPS estimate?
        Jaguar Animal Health’s EPS estimate is -$0.02.
          How many shares outstanding does Jaguar Animal Health have?
          Jaguar Animal Health has 287,224,150 shares outstanding.
            What happened to Jaguar Animal Health’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Jaguar Animal Health?
            Currently, no hedge funds are holding shares in JAGX
            ---

            Company Description

            Jaguar Animal Health

            Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
            ---

            JAGX Earnings Call

            Q1 2024
            0:00 / 0:00
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            vTv Therapeutics
            Idexx Laboratories
            Elanco Animal Health
            PAVmed
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis